Advertisement
Advertisement
SRPT
Sarepta Therapeutics,, Inc. Common Stock
20.72
USDSponsored
-0.20
-0.96%
Sep 15, 16:00 UTC -4
Closed
After-Market
20.45
-0.27
-1.32%
SRPT Earnings Reports
Positive Surprise Ratio
SRPT beat 19 of 43 last estimates.
44%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$361.49M
/$0.14
Implied change from Q2 26 (Revenue/ EPS)
-9.91%
/-380.00%
Implied change from Q3 25 (Revenue/ EPS)
-9.48%
/-1500.00%
Sarepta Therapeutics,, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, SRPT reported earnings of -0.05 USD per share (EPS) for Q2 26, missing the estimate of 0.26 USD, resulting in a -119.05% surprise. Revenue reached 401.25 million, compared to an expected 371.63 million, with a 7.97% difference. The market reacted with a +5.34% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 17 analysts forecast an EPS of 0.14 USD, with revenue projected to reach 361.49 million USD, implying an decrease of -380.00% EPS, and decrease of -9.91% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Sarepta Therapeutics,, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Sarepta Therapeutics,, Inc. Common Stock reported EPS of -$0.05, missing estimates by -119.05%, and revenue of $401.25M, 7.97% above expectations.
How did the market react to Sarepta Therapeutics,, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 5.34%, changed from $15.93 before the earnings release to $16.78 the day after.
When is Sarepta Therapeutics,, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Sarepta Therapeutics,, Inc. Common Stock's next earnings report?
Based on 17
analysts, Sarepta Therapeutics,, Inc. Common Stock is expected to report EPS of $0.14 and revenue of $361.49M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.